Efficiency without innovation is just organized failure.
For nearly three decades, a quiet architecture of nonprofit partnerships has been filling the space between what science can achieve and what markets will fund—delivering medicines for sleeping sickness, malaria in infants, and drug-resistant gonorrhea to populations that profit-driven development has long passed over. As global health systems face pressure to streamline and shift power toward country leadership, the question is not only how to spend less, but how to keep discovery alive for the diseases that afflict the most vulnerable. More than seventy-nine novel health tools reaching two and a half billion people suggest that innovation shaped by public purpose, rather than shareholder return, is not idealism—it is a proven method. The deeper challenge of this moment is ensuring that the pursuit of efficiency does not quietly dismantle the very engine that makes progress possible.
- Global health reform is urgently needed, but the drive for efficiency carries a hidden danger: stripping away innovation leaves a tidier system that cannot meet tomorrow's threats.
- Drug-resistant bacteria, emerging pathogens, and medicines that never reach the people who need them represent failures that market forces have no financial incentive to fix.
- Product development partnerships—nonprofit coalitions of governments, researchers, companies, and foundations—have spent three decades taking the risks that commercial actors cannot afford to take.
- Concrete breakthroughs like a single-dose oral cure for sleeping sickness, the first antimalarial designed for small infants, and a new antibiotic for drug-resistant gonorrhea show this model delivering where markets have failed.
- As funding tightens and power shifts toward country leadership, these partnerships are deepening collaboration, pooling expertise, and sharpening accountability—positioning themselves as a necessity, not a luxury.
The global health system has achieved remarkable things—child mortality down, HIV and malaria pushed back—but it is now straining under fragmentation, duplication, and donor-driven priorities that leave governments and communities on the margins. Reformers are right to call for a leaner architecture that puts countries in control. The danger is that in the pursuit of efficiency, the world strips out the innovation function it cannot afford to lose. Drug-resistant bacteria spread. New pathogens emerge. Millions still cannot reach medicines that already exist. A streamlined system that stops producing new tools is simply organized failure.
The market will not solve this on its own. A treatment for sleeping sickness offers no meaningful profit. An antimalarial for infants weighing two to five kilograms is too small a commercial opportunity. Drug-resistant gonorrhea strikes populations too poor to cover development costs. These are the diseases that fall into the gap between what science can do and what business will fund—and they fall hardest on children, newborns, pregnant women, and people in low-resource settings.
Product development partnerships exist precisely to close that gap. Operating as nonprofits, they bring together governments, researchers, companies, foundations, and civil society to develop health tools the market ignores. Over nearly three decades, they have delivered more than seventy-nine novel products to two and a half billion people. The Drugs for Neglected Diseases initiative produced acoziborole, a single oral dose that replaced weeks-long hospital regimens for sleeping sickness patients in remote areas. Medicines for Malaria Venture and Novartis developed Coartem Baby, the first antimalarial designed for the smallest infants. The Global Antibiotic Research and Development Partnership brought zoliflodacin to market—the first new antibiotic in decades targeting drug-resistant gonorrhea.
What distinguishes this model is that it spans the full chain from laboratory to patient. Research is shaped by what countries actually need, trials are conducted where disease burden is highest, and affordability is built into the design from the start. As global health shifts toward country leadership, these partnerships offer a working example of what that means in practice—not prescription from above, but genuine collaboration toward shared goals. Reform is overdue. But reform that forgets to protect innovation will eventually fail, and the mechanisms that treat health as a public good must remain at the center of whatever system comes next.
The global health system has saved millions of lives. Child mortality has plummeted. HIV, polio, and malaria have been pushed back. Yet the machinery that delivered these victories is now creaking under its own weight—starved of resources, fragmented across too many actors, slow to respond to what countries actually need.
Reformers are right to demand change. The current architecture wastes money through duplication, siloes knowledge, and leaves too much power in the hands of distant donors rather than the governments and communities closest to the problem. A leaner, more efficient system that puts countries in the driver's seat makes obvious sense. But there is a trap hidden in this logic: efficiency without innovation is just organized failure. The tools that worked yesterday will not work tomorrow. Drug-resistant bacteria are spreading. New pathogens emerge. Millions still cannot reach medicines, vaccines, and diagnostics that exist. Strip away the innovation function in pursuit of streamlining, and you end up with a system that is tidier but useless.
The real work, then, is figuring out how to reform global health while keeping the engine of discovery running. This is harder than it sounds, because the market alone will not do it. A vaccine for sleeping sickness does not generate the kind of profit that attracts pharmaceutical companies. A malaria treatment for babies weighing two to five kilograms is too small a market. Drug-resistant gonorrhea affects populations too poor to pay what development costs. These are the diseases that kill the most vulnerable—children, newborns, pregnant women, people in places with almost no money—and they fall into the cracks between what science can do and what business will fund.
Product development partnerships fill that gap. They are nonprofit organizations that bring together governments, researchers, companies, foundations, and civil society to develop health tools for problems the market ignores. By operating without the pressure to turn a profit, they can take risks commercial actors cannot. They can prioritize saving lives over shareholder returns. Over nearly three decades, these partnerships have delivered more than seventy-nine novel health tools to two point four billion people.
The results speak for themselves. The Drugs for Neglected Diseases initiative created acoziborole, a single-dose oral drug that has transformed treatment for sleeping sickness in remote areas where patients could never reach hospitals for the old multi-week regimens. The Medicines for Malaria Venture and Novartis together developed Coartem Baby, the first and only antimalarial designed specifically for infants in that narrow weight range. The Global Antibiotic Research and Development Partnership brought zoliflodacin to market—the first new antibiotic in decades developed solely to fight drug-resistant gonorrhea, one of the world's most urgent and most ignored threats. These are not theoretical victories. They are medicines in the hands of people who would otherwise have no options.
What makes this model work is that it operates across the entire chain from laboratory to patient. It does not treat discovery as separate from delivery, or research as separate from the real world. Partnerships collaborate with governments to understand what countries actually need, conduct trials in high-burden settings where the disease is worst, and ensure that new products are affordable and usable where they will be deployed. This is not innovation for innovation's sake. It is innovation shaped by the people it is meant to serve.
As global health systems shift toward country leadership, product development partnerships show what that actually looks like in practice. It is not prescription from above. It is partnership—governments, researchers, manufacturers, communities all working toward the same goal. The funding environment is tightening, which makes this approach not a luxury but a necessity. The three organizations behind this argument are deepening their own collaboration, pooling expertise, reducing duplication, and sharpening their accountability to the communities they serve.
Reform of the global health system is overdue. But reform that forgets to protect innovation will eventually fail. A country-led system still needs to produce the next generation of medicines, vaccines, and diagnostics. The mechanisms that work—partnerships that treat health as a public good rather than a commodity—must remain at the center of whatever comes next.
Citações Notáveis
We cannot meet today's health needs—let alone tomorrow's—with yesterday's tools.— Manica Balasegaram, Martin Fitchet, and Luis Pizarro
A country-led global health system must still deliver essential outputs like innovation, which can be achieved by strengthening the mechanisms that already work.— Manica Balasegaram, Martin Fitchet, and Luis Pizarro
A Conversa do Hearth Outra perspectiva sobre a história
Why does the global health system need product development partnerships? Isn't that just another layer of bureaucracy?
Because the market does not care about sleeping sickness or drug-resistant gonorrhea. These diseases kill people who cannot pay enough to make a profit. A partnership can take that financial risk. A company cannot.
But couldn't governments just fund pharmaceutical companies directly to make these drugs?
Governments lack the capacity and the will. They do not have the expertise to run drug development pipelines. Partnerships bring together the researchers, the manufacturers, the funders, and the communities in one place, so each part of the work actually talks to the others.
You mention seventy-nine health tools delivered to two point four billion people. That sounds impressive, but is it actually moving the needle on global health?
It is moving the needle for the people who have no other options. A baby with malaria in a low-resource setting now has a medicine designed for her weight. That did not exist before. That is not theoretical.
What happens if global health reform succeeds in making the system more efficient but partnerships lose funding in the process?
Then you have a more organized system that cannot innovate. You sustain yesterday's gains but cannot meet tomorrow's threats. That is the trap—efficiency without innovation is just managed decline.
So partnerships are not optional?
They are not optional if you want a global health system that actually works.